Daneng Li, MD, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, Liver Program Disease Team Lead, City of Hope, gives his take on the role of immuno-oncology (I-O) in managing hepatocellular carcinoma (HCC) considering the recent data.
